New Phase 3 Data Reinforces Safety, Efficacy of Linaclotide for Pediatric Functional Constipation

The new data was published in The Lancet Gastroenterology & Hepatology and highlighted additional efficacy endpoints from the study used to support linaclotide’s FDA approval in 2023.

Related Keywords

Rome ,Lazio ,Italy ,Georgee Batchelor ,Michael Shetzline ,Drug Administration ,University Of Miami ,Ironwood Pharmaceuticals Announces ,Ironwood Pharmaceuticals ,University Of Miami Health System Miguel Saps ,Miami Health System ,Miguel Saps ,Lancet Gastroenterology ,Endowed Chair ,Bristol Stool Form Scale ,Ironwood Announces Publication ,New Linaclotide Phase ,Adolescents Aged ,New Indication ,Functional Constipation ,Pediatric Patients Ages ,Linaclotide ,Linzess ,Chronic Idiopathic Constipation ,Irritable Bowel Syndrome ,Ribs ,Constipation ,Stool ,Bowel Movement ,